As of 2025-07-14, the Fair Value of BioCryst Pharmaceuticals Inc (BCRX) is -1.28 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 8.76 USD, the upside of BioCryst Pharmaceuticals Inc is -114.59%.
With the market price of 8.76 USD and our fair value calculation, BioCryst Pharmaceuticals Inc (BCRX) is not a good investment. Investing in BCRX stocks now will result in a potential loss of 114.59%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -182.80 | -184.10 | -247.10 | -226.54 | -88.88 | -185.88 |
| YoY growth | -67.86% | -0.71% | -34.22% | 8.32% | 60.77% | -6.74% |
| Market Cap (mil) | 1,833.03 |
| P/E | |
| Forward P/E |
| EPS | -0.26 |
| Avg earnings growth rate | -6.74% |
| TTM earnings | -53.47 |